Read More

Pfizer Surprises With Profit But Revolutionizing Cancer Treatment Is Its Best Chance Of Getting Back In The Saddle

On Tuesday, Pfizer Inc (NYSE: PFE) reported mixed results for its fourth quarter. Last year, Pfizer has responded to concerns related to its COVID-19 products being the rearview mirror with a cost-cutting program, internal restructuring and by getting deeper into oncology with its purchase of cancer drugmaker Seagen.

MRK